Inmagene

Global clinical stage biotech company is developing a portfolio of novel therapeutics for immunology-related diseases. The lead program, Izokebep (IMG-020), is a best-in-class inhibitor of interleukin-17A (IL-17A) that is in late-stage trials and is being studied for Hidradenitis Suppurativa Clinical Response (HiSCR) as well as psoriatic arthritis (PsA) and plaque psoriasis.